Literature DB >> 9618175

Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia.

R Yavari1, C Adida, P Bray-Ward, M Brines, T Xu.   

Abstract

The development of the sympathetic nervous system involves cell-cell interactions that regulate the fate and migration of progenitor neural cells. Recent evidence shows that focal membrane-bound protease activity is critical for such interactions. The Drosophila kuzbanian (kuz) gene is required in neurogenesis and encodes a highly conserved, membrane-bound metalloprotease- disintegrin closley related to theTNF-alphaconvertingenzyme (TACE). We have characterized the human and mouse kuz homologs and mapped human kuz to chromosome 15q22. During mouse embryonic development Kuz is expressed mainly in the sympathoadrenal and olfactory neural precursors. Once sympathoadrenal cells differentiate into chromaffin cells in the adult adrenal medulla, they no longer express Kuz. However, we found that tumors of sympathoadrenal origin, such as pheochromocytomas and neuroblastomas, overexpress Kuz. Further, transfection of a kuz construct lacking the protease domain, but not the full-length construct, induces neurite formation in PC12 chromaffin tumor cells. Taken together our results suggest a critical role for Kuz in regulation of sympathoadrenal cell fate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618175     DOI: 10.1093/hmg/7.7.1161

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.

Authors:  Sven Lammich; Dominik Buell; Sonja Zilow; Ann-Katrin Ludwig; Brigitte Nuscher; Stefan F Lichtenthaler; Claudia Prinzen; Falk Fahrenholz; Christian Haass
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

2.  The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.

Authors:  Sercan Ergün; Mustafa Ulasli; Yusuf Ziya Igci; Mehri Igci; Sevil Kırkbes; Ersin Borazan; Ahmet Balik; Önder Yumrutaş; Celalettin Camci; Ecir Ali Cakmak; Ahmet Arslan; Serdar Oztuzcu
Journal:  Mol Biol Rep       Date:  2014-10-16       Impact factor: 2.316

3.  ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism.

Authors:  S Cal; J M Freije; J M López; Y Takada; C López-Otín
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

4.  ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor.

Authors:  Takahide Kodama; Eiji Ikeda; Aiko Okada; Takashi Ohtsuka; Masayuki Shimoda; Takayuki Shiomi; Kazunari Yoshida; Mitsutoshi Nakada; Eiko Ohuchi; Yasunori Okada
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

5.  ADAM10 negatively regulates neuronal differentiation during spinal cord development.

Authors:  Xin Yan; Juntang Lin; Venkata Ajay Narendra Talabattula; Carolin Mußmann; Fan Yang; Andreas Wree; Arndt Rolfs; Jiankai Luo
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

Review 6.  Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms.

Authors:  Kristina Endres; Thomas Deller
Journal:  Front Mol Neurosci       Date:  2017-03-17       Impact factor: 5.639

7.  Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation.

Authors:  Erin K Nyren-Erickson; Michael Bouton; Mihir Raval; Jessica Totzauer; Sanku Mallik; Neville Alberto
Journal:  J Negat Results Biomed       Date:  2014-04-01

8.  Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo.

Authors:  Jonathan R Fisher; Clare E Wallace; Danielle L Tripoli; Yvette I Sheline; John R Cirrito
Journal:  Mol Neurodegener       Date:  2016-06-18       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.